George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Troublesome, no not Shaun of the Dead..but if Shauns surname was Scruggs...well..
https://youtu.be/Q0ZEmLosVXE
Not sure who the rather portly feller with the gun might be :)
All in fun so hope no one gets offended.
Apologies for double post. First one dissapeared into the ether. Weak internet at moment here.
Longstop date was last moved out to 30th April 2021. Were all aware that Covid will have caused some problems but lets hope theres no more delays or investors patience will be stretched very thin and sp could suffer.
Longstop date is 30th April.
Nobodies denying that Covid will have caused delays but lets hope theres no more excuses or investors patience will really be stretched to the limit.
Theres a few come out of the woodwork every time boris and the poor old tories are given a hard time though ive noticed wilson. They dont need or deserve to be defended imo. As government of the day (left or right) your there to be shot down if your not performing your duties I havent been back for a few years but NOTW gone?
Well it has been a few years since I was there.
What about the daily sport..dont tell me thats gone too :/
Kitzie not sure why you and some others are so quick to attack the Guardian. Isnt it a good thing that there are some papers with a centre or left leaning slant, so as to give a balance?
For the centre/left theres..
Daily mirror
Guardian
Observer
Independent
For the centre/right theres..
Express
Mail
Sun
Star
News of The World
Or for a more intellectual read, the Telegraph.
Plenty of choice
Each to their own.
6)
"Successful implementation of the analysis of saliva samples from Astra Zeneca personnel using the genesig® test.
In early 2020, AstraZeneca implemented an internal voluntary SARS-CoV-2 screening program for asymptomatic employees in the UK and Sweden using Novacyt's COVID-19 genesig® test. As of February 2021, approximately 70,000 PCR tests for SARS-CoV-2 have been performed at AstraZeneca internal testing centers worldwide, of which 54,000 are based on saliva samples. Following the implementation of saliva testing, employee uptake has increased by approximately 4 times and over 90% of 1,062 employees surveyed expressed a preference for this method over oropharyngeal (throat) or nasopharyngeal swabs. (nasal) The study highlights the 90% uptake of saliva testing for asymptomatic patients and the excellent detection rates of 0.33 copies of the
Graham Mullis, CEO of Novacyt, said:
“Novacyt continues to build on its reputation as an innovative group and its position in the constantly evolving COVID-19 testing market, to continue to create value and support clinicians and laboratories in a global context. It should be noted that after its launch, our PROmate ™ test was well received by users, opening up new commercial perspectives, for rapid PCR tests, including in the private markets. In addition, we look forward to presenting our long term plans for Novacyt in the second quarter of this year, as we continue to define our strategy to ensure sustainable and long term growth. "
5)
"Development of the PROmate ™ two target gene assay
Following the initial success of the PROmate ™ assay aimed at improving workflow efficiency when used with the Group's q16 and q32 instrument platforms, Novacyt is developing a two-target gene version of this assay to support markets and use cases where a two-gene test is required. The same operational benefits will be available to customers.
Successful clinical trial with Queen Mary University in London
As announced on November 16, 2020, Queen Mary University of London (QMUL) completed the clinical trial using the Group's COVID-19 rapid test platforms in nursing homes. At the end of this test, more than 4,500 samples and their results were recorded. Data analysis is now underway and results are expected to be reported in the second half of 2021.
Obtaining and publishing the validation of PROmate ™ TVG
On January 29, 2021, the United Kingdom announced the in-service validation of the PROmate ™ trial using the Group's q16 and q32 PCR platforms. This trial was successfully completed in December 2020 and published by the Technology Validation Group (TVG) in January 20218.
The independent study was carried out in four British National Health Service (NHS) laboratories with 759 samples, of which 242 were positive and 517 were negative. Analysis of the results demonstrated a very high level of sensitivity and specificity, so the performance of PROmate ™ was found to meet the Medicines and Health Products Regulatory Agency standard for point of care. (rapid tests). This TVG accreditation supports the use of the q16 / q32 device and PROmate ™ in a bedside environment, as well as its current deployment across the NHS and in international markets. PROmate ™ is the only direct PCR test validated by TVG, reaffirming the Group's position at the forefront of PCR technology."
4)
"Development of the COVID-19 LAMP (loop-mediated isothermal amplification) test
As announced on November 16, 2020, the Group has completed the first trials of its LAMP technology for its q16 and q32 instrument platform and other existing LAMP platforms and has demonstrated very encouraging initial results. Novacyt continues to assess the opportunities offered by the LAMP test and will launch its technology based on demand.
Development of a new panel of tests to detect fungal infections of aspergillosis
Aspergillosis is an infection caused by the aspergillus fungus, common in patients4 with weakened immune systems and, more recently, has been associated with co-infection in patients with SARS CoV-25 and pulmonary aspergillosis. associated with COVID-196. The infection is linked to the long-term ventilation of the patients. Apart from SARS-CoV-2 infections, aspergillosis also remains a potentially serious respiratory infection affecting around 5 million patients worldwide7.
Novacyt's new multiplex PCR test panel will detect the five main aspergillus subtypes and will work on the Group's q32 instruments and also on other platforms. Novacyt plans to start validation studies soon, allowing a commercial launch to be considered in the second half of 2021.
Once launched, the new test panel will be the second product in Novacyt's COVID-19 + line, following the launch of the Winterplex ™ multiplex winter test panel in August 2020. This launch is also part of Novacyt's strategy to target to expand its portfolio of innovative respiratory medical diagnostic products."
3)
"CE marked COVID-HT Direct test launched
Novacyt announces the launch of its new generation of high-throughput COVID-19 PCR test (COVID-HT Direct), which has also obtained the CE mark on the basis of data validated by independent bodies. This follows the launch of the Group's first COVID-19 high-capacity PCR test (COVID-HT) in June 2020. The new test eliminates the need for automated extraction systems in a high-throughput PCR laboratory, reducing time processing, costs and labor up to 30%. The new COVID-HT Direct test uses pharyngeal swabs collected in viral transport media (without guanidine) and physiological saline. COVID-HT Direct is already in use in
Development of a COVID-19 LFT test
The Group is continuing its development work on an IgG antibody lateral flow test (LFT) which will be used as a rapid antibody test intended for professional use. An LFT is an easy-to-use diagnostic device, used to confirm the presence or absence of a pathogen or biomarker, and it takes about 10 to 20 minutes or less to get a result.
The Group plans to launch its LFT in the second quarter of 2021, a little later than expected, as it has made the strategic decision to develop a new generation of LFT to detect the neutralizing antibodies generated by a successful immunization and thus to help control the effectiveness of future vaccines 3. The Group believes this is a good illustration of how it can broaden the revenue outlook related to COVID-19, as demand for testing will continue to grow."
2)
"The Group continues to support expert clinical research teams undertaking clinical trials in the global COVID-19 testing market:
Queen Mary University in London has successfully completed the clinical trial of rapid tests in nursing homes using the rapid PCR system developed by the Group.
Variant surveillance study started in UK, US and Latin America
Novacyt's COVID-19 product portfolio continues to obtain independent approvals and accreditations:
The Technical Validation Group (TVG) of the UK Department of Health and Social Affairs (DHSC) has announced that the in-service validation of PROmate ™ has been successfully completed.
Astra Zeneca reported successful implementation of staff saliva testing using Novacyt's COVID -19 genesig® test
Development of the SNPsig® product portfolio
With the rapid emergence of major variants of the SARS-CoV-2 virus, the Group has expanded its polymerase chain reaction (PCR) genotyping portfolio, SNPsig®, announced on February 2, 2021, to incorporate detection the new variant of concern (VOC-202102/02) 1, first identified in the Bristol and California variant (B.1.429 / CAL.20C) 2. These extensions demonstrate the Group's ability to match the rapid evolution of the virus with real-time bioinformatics monitoring and accelerated product development. The variant surveillance study, also announced on February 2, 2021, began at sites in the UK, US and Latin America,"
1)
"Novacyt (ALTERNEXT: ALNOV; AIM: NCYT), global specialist in clinical diagnostics, provides an update on the progress of its ongoing research and development (R&D) programs, including the development of its product portfolio, clinical trials and the publication of independent validations of the Group's COVID-19 tests.
Along with the current objective of continuing to optimize the opportunities offered by the COVID-19 test, the Group is also developing its strategy with a view to providing a long-term sustainable diagnostic activity. Novacyt intends to present these plans in the second quarter of 2021.
By expanding its portfolio of COVID-19 products, the Group continues to respond to the rapid evolution of the diagnostics market:
Extension of the SNPsig® portfolio to detect new variants of concern of SARS-CoV-2, including a specific variant predominant in the United States
Launch of CE-marked COVID-HT Direct tests, a new generation of direct screening tests for SARS-CoV-2 by PCR for high-throughput laboratories
Development of the COVID-19 Antibody Lateral Flow Test (LFT)
Development of the COVID-19 LAMP (loop-mediated isothermal amplification) test
Development of a panel of innovative tests for the detection of aspergillus, a respiratory fungal infection associated with a risk of co-infection in patients with COVID-19.
Development of a two-target PROmate ™ test to address markets that use this screening method"
Van..youve been one of the better posters here and I hope youll continue to be but I think its inevitable that your going to get a few negative comments if your discussing another company your invested in here.
Its not about Avacta for me..its the whole LFT thing. They are bl**dy useless, no matter who manufactures them but our government insists on flying in the face of the scientific evidence, just so they can grab some headlines.
Theyre doing great with the vaccinations so why not use the most accurate (PCR) tests, or at the very least test every 'negative' LFT test with a PCR test to be sure..like the french apparently do, and do more to stop the entry of infected people from around the world, which they should have done from the start, like New Zealand, then tens of thousands of our loved ones would still be with us.
Sorry, ended up as a bit of a rant but people have lost loved ones because of LFT tests, most of which admittedly (and shockingly) were overpriced substandard chinese cr@p, but none can be said to be better than tossing a coin and hoping for the best imo. Sorry if that offends those invested in LFT tests and best of luck to them but I personally wont invest in them on principle.
Tin hat on and..jumping into the nearest foxhole.
Good point about kids having low viral loads, even at peak of infection Deas.
It really makes a mockery of what the government are intent on forcing through. Ignore the science in favour of a bit of headline grabbing.
Pity us while this lot are in charge.
Not sure if its the E484K and N501Y variants or something new based on those...
“Out of 50 samples total, there were 37 samples that had the mutations of concern,” Loreche said.
She said 58% – or 29 out of 50 – of the samples had "co-occurrence" where both of the mutations were present.
DOH7 said they were investigating the mutations as a "variant of concern" but said there was not enough information to conclusively call it a variant yet.
New variants certainly on the rise though and very worrying for effectiveness of vaccines going forward.
Looks like vaccines will have to be constantly tested and tweaked against new variants.
Bad news humanity of course but good news for Novacyt.
Lots of noise and distractions at times where I am at present here in the Philippines porky. Just briefly heard it on the news and wasnt able to hear properly. Just heard two new variants found in Cebu (Philippines)
Just checked online and found this..
https://www.rappler.com/nation/doh-region-7-says-covid-19-variant-of-concern-detected-cebu-city-february-2021